Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
  • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
  • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
  • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
  • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
  • C12R2001/00—Microorganisms ; Processes using microorganisms
  • C12R2001/91—Cell lines ; Processes using cell lines

Definitions

• the present disclosure relates to a method for producing collagen-producing plants or isolated plant cells, a nucleic acid construct used therein, and a method for producing collagen protein using the plants or isolated plant cells.
• Collagen is a family of extracellular matrix proteins found in all mammalian connective tissues, and the collagen molecule contains a triple helical region of three polypeptides called alpha chains. Collagen such as type I collagen is involved in various biological reactions such as early animal development, organ formation, cell adhesion, cell proliferation, hematopoiesis, wound healing, and tissue reconstruction. Collagen is widely used in the medical, therapeutic, cosmetic, food, and other fields due to its structural characteristics and low immunogenicity (Non-Patent Document 1: Ruggiero et al., 2000, FEBS Letter, 2000, Vol. 469, pp. 132-136. Non-patent document 2: Merle et al., FEBS Letter, 2002, Vol. 515, pp.
• Non-patent Document 2 Merle et al., FEBS Letter, 2002, Vol. 515, pp. 114-118, Patent Document 1: International Publication No. 2006/035442).
• collagen is a protein with a complex structure that has a triple helical structure formed by three peptide chains. Further technical improvements were required.
• plant cells used for protein production such as tobacco plants, have enzymes that cleave at positions that are shifted from the original human pro-region cleavage site, and even if they are simply expressed in plant cells, It has been difficult to produce high-quality collagen whose structure completely matches that of human collagen. Therefore, even if collagen is simply expressed within plant cells, it has been difficult to produce collagen of a quality that can be used in the medical, therapeutic, cosmetic, food, and other fields.
• An object of the present disclosure is to provide a further improved method for producing collagen in plants or isolated plant cells, which can be used in the pharmaceutical field, therapeutic field, cosmetic field, food field, etc. .
• the inventors of the present disclosure have conducted intensive tests and studies on a method for producing collagen in plants or isolated plant cells, and have found that by transiently expressing procollagen in plant cells, By discovering that the N-terminal cleavage of procollagen in plants is suppressed, they succeeded in efficiently producing collagen in plants or isolated plant cells, and completed the present invention.
• the present disclosure provides a method for producing procollagen or collagen from a plant or isolated plant cell, comprising the step of transiently expressing procollagen in the plant or isolated plant cell. provide.
• the present disclosure provides collagen or procollagen produced in a plant or isolated plant cell.
• the present disclosure provides a nucleic acid construct for producing collagen or procollagen in a plant or isolated plant cell.
• the present disclosure provides a vector containing a nucleic acid construct for producing collagen or procollagen in a plant or isolated plant cell, and a plant or isolated plant cell containing the vector. do.
• the present disclosure provides procollagen or collagen having a non-natural sequence encoded by a nucleic acid construct for producing collagen or procollagen in a plant or isolated plant cell.
• the present disclosure provides procollagen or a composition comprising collagen.
• this disclosure provides: [Item 1] A) providing a plant or isolated plant cell containing a nucleic acid construct encoding procollagen; B) A step of transiently expressing procollagen in a plant body or isolated plant cells; C) step of separating procollagen or collagen secreted extracellularly in step B; A method for producing procollagen or collagen from a plant body or isolated plant cells, comprising: [Item 2] A method for producing procollagen or collagen from a plant body or isolated plant cells, which comprises a step of cleaving the N-terminus or C-terminus of procollagen secreted extracellularly after step B. [Item 3] 3.
• nucleic acid construct comprises a nucleic acid sequence encoding procollagen having 80% or more amino acid sequence identity to native procollagen.
• nucleic acid construct contains a nucleic acid sequence encoding full-length procollagen and has a mutation such that the N-terminus of procollagen is not cleaved in plant cells.
• Procollagen or collagen produced by the method according to any one of items 1 to 4.
• nucleic acid construct A nucleic acid construct expressing collagen used in the method according to any one of items 1 to 4.
• An expression vector comprising the nucleic acid construct according to item 6.
• [Item 8] A plant or isolated plant cell comprising the nucleic acid construct according to item 5 or the expression vector according to item 7.
• [Item 9] A procollagen or collagen encoded by the nucleic acid construct according to item 6, which has a non-natural amino acid sequence.
• [Item 10] The procollagen or collagen according to item 9, wherein a heterologous peptide is fused to the N-terminal pro region.
• a pharmaceutical composition, cosmetic composition, or food composition comprising procollagen or collagen produced by the method according to any one of items 1 to 4, or procollagen or collagen according to item 9 or 10.
• the present disclosure has the effect of providing a further improved method for producing collagen in plants or isolated plant cells, which can be used in the pharmaceutical field, therapeutic field, cosmetic field, food field, etc.
• FIG. 1a is a schematic diagram showing the structure of a type I collagen ⁇ 1 expression cassette.
• FIG. 1b is a schematic diagram showing the structure of a type I collagen ⁇ 2 expression cassette.
• FIG. 1c is a schematic diagram showing the structure of prolyl 4-hydroxylase ⁇ subunit (P4H ⁇ ) and prolyl 4-hydroxylase ⁇ subunit (P4H ⁇ ) expression cassettes.
• FIG. 1d is a schematic diagram showing the configuration of a lysyl hydroxylase 3 (LH3) expression cassette.
• FIG. 1e is a schematic diagram showing the structure of a bone morphogenetic protein 1 (BMP1) expression cassette.
• FIG. 1f is a schematic diagram showing the structure of the Tomato bushy stunt virus-derived RNA silencing suppressor p19 expression cassette.
• Figure 2 shows that full-length collagen protein having an N-terminal pro-region and a C-terminal pro-region is accumulated in the plant by transiently expressing the type I collagen ⁇ 1 expression cassette in a Nicotiana benthamiana plant expression system. It is a figure which shows that it was confirmed.
• Lane 3 shows that the full-length collagen protein expressed from the type I collagen ⁇ 1 expression cassette was extracted.
• Lanes 4 to 18 show that the full-length collagen protein expressed from the type I collagen ⁇ 1 expression cassette having cleavage site mutations corresponding to various proteases was cleaved by the corresponding proteases.
• FIG. 3 is a diagram showing that fluorescence was confirmed by irradiating an extract of a green fluorescent protein (GFP)-fused collagen ⁇ 1 extract with excitation light.
• Figure 4 shows a Western blot experiment confirming that ⁇ 1 and ⁇ 2 collagen proteins accumulate simultaneously in cell bodies by co-expressing type I collagen ⁇ 1 expression cassette and type I collagen ⁇ 2 expression cassette in a plant expression system. It is a figure showing a result.
• FIG. 5 is a diagram showing the results of a test that confirmed the expression of ⁇ 1 and ⁇ 2 collagen proteins using a mass spectrometer.
• Collagen is composed of three peptide chains called ⁇ chains, and each peptide synthesized from mRNA by ribosomes bound to the endoplasmic reticulum membrane of the cytoplasm is transferred into the endoplasmic reticulum as it is synthesized, and the S of each C-terminal A triple-chain procollagen molecule consisting of three peptides is formed by -S bonding reaction, etc.
• Triple-chain procollagen molecules secreted from the endoplasmic reticulum to the outside of the cell via the Golgi apparatus become mature triple-chain collagen by cleavage at the N-terminus and C-terminus (Ricard-Blum, Cold Spring Harb Perspective Biol. 2011 Jan 1;3(1):a004978).
• Mature triple-chain collagen is classified into various types, such as type I collagen, type II collagen, type III collagen to type XXVIII collagen, depending on the type, combination, overall structure, or characteristics of the constituent ⁇ chains.
• type I collagen is mainly composed of two ⁇ 1 peptides and one ⁇ 2 peptide
• type II collagen is composed of three ⁇ 1 peptides.
• Each ⁇ chain produces further variations due to differences in the splicing mode during biosynthesis
• type III collagen is composed of three ⁇ 1 peptides like type II collagen, but the splicing form of each ⁇ chain is different.
• Some types of mature triple chain collagen are further crosslinked with each other to form a fibrous structure, and some types of mature triple chain collagen form a network structure. These various collagens are produced in various places within the body and play various biological functions (Ricard-Blum, Cold Spring Harb Perspect Biol. 2011 Jan 1; 3 (1): a004978).
• the presently disclosed invention relates to a method for producing collagen in plants or isolated plant cells in order to mass-produce such collagen and use it in the pharmaceutical field, therapeutic field, cosmetic field, food field, etc.
• a method for producing collagen in plants or isolated plant cells in order to mass-produce such collagen and use it in the pharmaceutical field, therapeutic field, cosmetic field, food field, etc.
• N-terminus and C-terminus are cleaved by enzymes to form mature collagen molecules.
• procollagen is expressed in plant cells
• the N-terminus and C-terminus are truncated in the plant cells, resulting in a significant decrease in water solubility.
• the N-terminal cleavage site that is cleaved within the plant cell is located closer to the C-terminus than the site where the N-terminus is originally cleaved when procollagen matures into collagen, and the procollagen expressed within the plant cell.
• the N-terminus of the mature collagen obtained from this method is shorter than that of natural mature collagen. Furthermore, the location of the N-terminal cleavage site that is cleaved within plant cells is unknown. Due to cleavage at these non-natural locations within plant cells, collagen produced within plant cells may have different properties than native collagen.
• the inventors of the present disclosure have discovered that N-terminal cleavage of procollagen in plant cells can be suppressed by making collagen expression in plant cells transient. Furthermore, by discovering amino acid mutations that can suppress the cleavage of the N-terminus or C-terminus of procollagen in plant cells or during the production process, and expressing procollagen with these mutations, procollagen or collagen secreted outside the cells can be produced. It became possible to efficiently collect. Furthermore, the N-terminal and C-terminal extension regions of procollagen are cleaved with a desired enzyme, and the amino acid sequences of the N-terminus and C-terminus of the mature collagen molecule after cleavage are the same as the amino acid sequence of the natural mature collagen molecule. By introducing the enzyme recognition sequence for collagen into the collagen gene, it became possible to convert procollagen into mature collagen molecules in a desired step.
• the term “substantially” has the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains, but for example, It is intended to encompass the desired state and states that are unavoidably unachieved due to biological or chemical properties, taking into account that the state may not be fully achieved.
• compositions that "contains" A may include, in addition to only A, another component, B.
• compositions As used herein with respect to a composition, the terms “consisting of” or “consisting of” have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains, but Used to indicate the components that exclusively make up the composition. For example, a composition “consisting of” A contains exclusively A. However, in one embodiment, a composition “consisting of” A includes embodiments containing contaminants other than A that are unavoidable in manufacturing based on biological and chemical properties.
• identity of amino acid sequences or base sequences refers to the number of matched amino acids when two sequences are aligned so that the amino acids or bases of the two amino acid sequences to be compared match as many as possible. Alternatively, it is the number of bases divided by the total number of amino acids or the number of bases, expressed as a percentage.
• gaps may be inserted into one or both of the two sequences to be compared, if necessary.
• sequence alignment can be performed using well-known programs such as BLAST, FASTA, CLUSTAL W, and the like. When a gap is inserted, the total number of amino acids or bases mentioned above is the number in which one gap is counted as one amino acid or base.
• the percent identity is the total number of amino acids or bases in the longer sequence, and the number of matched amino acids. Or calculated by dividing the number of bases. However, if the sequence to be compared is connected to any other sequence, only the corresponding region is extracted and the sequences are compared to calculate identity.
• procollagen or collagen expression is "transient” has the same meaning as commonly understood by those skilled in the art to which this disclosure pertains, but typically procollagen or collagen expression is “transient”. It means that collagen or a nucleic acid sequence encoding collagen is expressed within a host cell without being integrated into the genome of the host cell. Such transient expression can be achieved, for example, using viral vectors.
• the present disclosure provides a method of producing collagen in a plant or isolated plant cell.
• procollagen or collagen molecules are secreted extracellularly by transiently expressing a nucleic acid construct containing a nucleic acid encoding procollagen in a plant body or isolated plant cells. and finally produce procollagen or collagen molecules.
• the procollagen or collagen production method of the present disclosure includes the following steps.
• nucleic acid construct used in the above step A) "Preparing a plant or isolated plant cell containing a nucleic acid construct encoding procollagen" is typically as follows (in a plant or isolated plant cell). Nucleic acid construct for use in collagen production).
• the type of collagen produced in the procollagen or collagen production method of the present disclosure is not particularly limited, and by combining an appropriate ⁇ chain-encoding nucleic acid construct, collagen type I, type II collagen, type III collagen, etc. can be produced. , can produce any collagen.
• collagens having non-natural amino acid sequences or fused with heterologous peptides can be produced, as described below (Procollagen or Collagen Encoded by Nucleic Acid Constructs).
• Examples of plants used in the procollagen or collagen production method of the present disclosure include plants of the genus Nicotiana, moss plants (P. patens, etc.), potatoes (S. tuberosum, etc.), grasses (O. sativa, etc.), Examples include plants of the family Brassicaceae and lettuce, but plants of the genus Nicotiana are preferred. Examples of plants of the genus Nicotiana include, but are not limited to, N. benthamiana, N. tabacum, N. excelsior, and the like.
• step B) "the step of transiently expressing procollagen in a plant or isolated plant cell"
• an expression vector such as a viral vector containing a nucleic acid sequence encoding procollagen is typically used. It is expressed in plants or isolated plant cells without being integrated into the host cell genome.
• transiently expressing procollagen By transiently expressing procollagen, it is possible to suppress N-terminal cleavage within plant cells.
• Transient expression of procollagen in a plant body or isolated plant cells can be performed by a method known to those skilled in the art to which this disclosure pertains, and the expression amount, expression period, etc. of procollagen can be determined by Those skilled in the art can appropriately adjust the vector used, the promoter, the composition of the medium, the culture conditions, etc., without departing from the spirit of the present disclosure.
• the virus proliferates within a plant infected with the virus or isolated plant cells, and a large amount of collagen is produced within the plant cells.
• collagen or procollagen can be extracted and recovered from plant tissues such as leaves after cultivating the plant for about 3 to 15 days after inoculation with a virus.
• step C) "separating the procollagen or collagen secreted extracellularly in step B"
• any method known to those skilled in the art to which this disclosure pertains can be used.
• C. D. Mount et al. Archives of Biochemistry and Biophysics, 240 33 (1985), U. H. Gregory and I. R. Willshire, Hoppe-Sayler's Z. Physiol. Chem. , 356, 1765 (1975) can be used, but are not limited thereto. More specifically, for example, when collagen is expressed in tobacco plants to produce collagen or procollagen, frozen leaves of tobacco plants are ground in an appropriate buffer, and collagen or procollagen is extracted from the buffer by salting out. Procollagen can be extracted and purified.
• the procollagen or collagen production method of the present disclosure may include, after step B, a step of cleaving the N-terminus or C-terminus of the procollagen secreted extracellularly.
• the cleavage can be performed by treating procollagen with chemical treatment, enzymatic treatment, or a combination thereof. At least a part of the chemical or enzymatic treatment is performed outside the plant cells, and can be performed during the culturing process, during the extraction and purification process, after the extraction and purification process, and the like.
• the C-terminus of natural procollagen can be excised by extracting and purifying full-length procollagen in an acidic environment.
• the N-terminus or C-terminus of procollagen can be excised with a protease (proteolytic enzyme) after the extraction and purification step.
• a protease proteolytic enzyme
• the excision reaction can be improved. Specificity can be improved and high product stability can be obtained.
• full-length procollagen can be used as a raw material for bioink for bio-3D printers, and enzymes that cleave the N-terminus or C-terminus after constructing the three-dimensional structure with the bio-3D printer (e.g. :BMP1) can also be applied to make the triple helix structure stronger. This process is equivalent to "developing" photographic film before the widespread use of digital cameras.
• native mature collagen can be produced from native procollagen by using an enzyme that cleaves the N-terminus and C-terminus of native procollagen in mammalian cells.
• enzymes that cleave the N-terminus and C-terminus of natural procollagen include Procollagen N-Endopeptidase, BMP1, and the like.
• enzymes that cleave the N-terminus and C-terminus of natural procollagen include Procollagen N-Endopeptidase, BMP1, and the like.
• by utilizing amino acid mutations and introducing desired protease recognition sequences into the N-terminus and C-terminus of procollagen it becomes possible to utilize the corresponding protease.
• examples of such enzymes include, but are not limited to, HRV3C, Furin, and Enterokinase.
• the recognition sequences and cleavage sites of HRV3C, Furin, and Enterokinase are as follows.
• the method for producing procollagen or collagen of the present disclosure may include a step of post-translationally modifying procollagen or collagen.
• the stability of procollagen or collagen can be improved by post-translationally modifying it, such as with P4H ⁇ , P4H ⁇ or LH3.
• the step of performing post-translational modification can be performed at any time after translation of the procollagen or collagen, and is performed within the plant cell or at a stage after secretion from the plant cell. be able to.
• post-translational modification can be performed within the plant cell, such as within the endoplasmic reticulum.
• at least a portion of the post-translational modification is performed at a location other than the vacuole of the plant cell.
• the present disclosure provides procollagen or collagen produced in plants or isolated plant cells.
• collagen that has been conventionally provided in the fields of medicine, cosmetics, and food products is often provided by decomposing collagen fibers, etc., which are polymerized collagen molecules existing in living tissues. Some of the structure and function of collagen had been lost.
• the procollagen or collagen produced in the plants or isolated plant cells of the present disclosure can be produced without undergoing such decomposition processes, so that the structure and function of collagen can be more fully maintained. It is possible to maintain it in a stable condition.
• the procollagen produced by the production method of the present disclosure includes procollagen with an N-terminus and a C-terminus.
• procollagen can be produced by transiently expressing a nucleic acid construct containing a nucleic acid encoding natural procollagen in plant cells, and then extracting and purifying the procollagen secreted outside the cells. I can do it.
• the procollagen produced in the present disclosure includes procollagen having a naturally occurring amino acid sequence.
• the amino acid sequence of procollagen having the natural type sequence is the same as that of natural procollagen, it may differ in post-translational modification status and the like depending on various conditions in the production process.
• the procollagen produced according to the present disclosure includes a non-natural procollagen having an amino acid mutation at the N-terminal cleavage site, the C-terminal cleavage site, or both sites.
• the mutation suppresses procollagen cleavage within plant cells or during the production process.
• the mutation provides a recognition sequence corresponding to the desired protease.
• the mutation provides a sequence that induces cleavage by chemical treatment during the production process.
• Amino acid mutations at the N-terminal cleavage site or C-terminal cleavage site of non-natural full-length procollagen may ultimately produce native mature collagen, and amino acid mutations at the N-terminus, C-terminus, or both termini It may also produce mature collagen having a native sequence.
• the above amino acid mutations may be amino acid additions, deletions, substitutions, or combinations thereof with respect to the natural amino acid sequence.
• the procollagen produced by the production method of the present disclosure includes N-terminally devoid procollagen and N-terminally devoid procollagen in which only one of the N-terminus or the C-terminus has been excised.
• the N-terminus-deleted procollagen has a different N-terminus than that obtained by intracellular ablation in plant cells.
• the procollagen lacking the N-terminus or C-terminus can be produced by treating extracellularly secreted full-length or incomplete-length procollagen with chemical treatment, enzymatic treatment, or a combination thereof. can.
• the procollagen produced according to the present disclosure includes one in which a peptide having a specific function is fused to the N-terminus, the C-terminus, or both.
• the peptide to be fused is not particularly limited, and may be a peptide derived from a foreign protein or a newly synthesized non-natural peptide.
• peptides that promote extracellular secretion, affinity peptides that can be used to purify procollagen, labeled peptides that generate fluorescence, and the like can be used.
• the fused peptide can be fused to procollagen using linker sequences known to those skilled in the art to which this disclosure pertains.
• a partial region or the entire region of the fused peptide can be excised from the procollagen by chemical or enzymatic reaction.
• the mature collagen produced according to the present disclosure has natural amino acid sequences at the N-terminus and C-terminus.
• the collagen produced according to the present disclosure has a non-natural amino acid sequence at at least one of the N-terminus and C-terminus.
• the non-natural amino acid sequence at the N-terminus is different from that produced by intracellular excision in plants.
• the procollagen or collagen produced in the present disclosure includes those having any amino acid mutations other than those described above. In one embodiment, the procollagen or collagen produced in the present disclosure includes a fusion of all or a partial region of procollagen or collagen with another peptide other than those described above.
• nucleic acid construct for use in collagen production in plants or isolated plant cells provides nucleic acid constructs for use in collagen production in plants or isolated plant cells.
• the nucleic acid construct of the present disclosure has a nucleic acid sequence encoding at least one ⁇ chain constituting collagen.
• a nucleic acid construct of the present disclosure has a sequence that expresses procollagen.
• the procollagen includes procollagen with various mutations mentioned above (collagen produced in plants or isolated plant cells) and procollagen fused with other peptides.
• the type of ⁇ chain encoded by the nucleic acid construct of the present disclosure is not particularly limited, and can encode any of ⁇ 1, ⁇ 2, and their splice isomers.
• nucleic acid constructs of the present disclosure may be DNA, RNA, or any analog thereof known to those skilled in the art to which the present disclosure pertains.
• the nucleic acid construct of the present disclosure may contain a non-natural base, and may also contain a hydrocarbon chain or a peptide chain as a part thereof.
• the nucleic acid construct of the present disclosure can be prepared by conventional chemical synthesis methods or genetic engineering techniques known to those skilled in the art to which the present disclosure pertains. For example, synthesis can be performed by synthesizing cDNA having a naturally occurring sequence, and then using this cDNA as a template and introducing appropriate mutations using appropriate primers. Alternatively, a DNA construct can be synthesized by dividing the nucleic acid construct to be synthesized into several short regions, chemically synthesizing a plurality of DNA fragments, and linking each fragment using the known fusion PCR method. RNA constructs can be prepared by transcription reactions from DNA constructs.
• any method known to those skilled in the art to which this disclosure pertains can be used.
• those skilled in the art can use methods such as, but not limited to, site-directed mutagenesis methods such as the Kunkel method and the Gapped Duplex method, overlap extension PCR (overlap extension PCR) methods, and QuikChange methods.
• the nucleic acid construct of the present disclosure may include a nucleic acid fragment for transient expression in a plant.
• a nucleic acid fragment encoding an appropriate RNA polymerase promoter e.g., phage polymerase promoter such as T7 promoter
• viral replicase e.g., transfer protein, coat protein, etc.
• T7 promoter e.g., T7 promoter
• viral replicase e.g., transfer protein, coat protein, etc.
• the nucleic acid construct of the present disclosure may include a nucleic acid fragment encoding an enzyme or the like useful for stably expressing collagen in a plant body.
• it can contain a nucleic acid fragment encoding P4H ⁇ , P4H ⁇ , LH3, etc., which enhance collagen stability, or a combination thereof.
• enzymes derived from various organisms can be used. For example, enzymes derived from nematodes, mice, humans, etc. can be used.
• part or all of the nucleic acid fragments encoding these enzymes may be included in a second nucleic acid construct that is separate from the nucleic acid construct that includes the nucleic acid encoding the alpha chain of procollagen.
• a first nucleic acid construct comprising a nucleic acid encoding the alpha chain of collagen may be used in combination with the second nucleic acid construct.
• first nucleic acid construct containing a nucleic acid encoding the alpha chain of procollagen and a second nucleic acid construct containing a nucleic acid fragment encoding an enzyme etc. are used in the same plant or isolated.
• the enzyme may be introduced into a plant cell, or may be introduced into a different plant or isolated plant cell so that the enzyme reacts with procollagen secreted outside the cell.
• the present disclosure provides vectors containing nucleic acid constructs for use in collagen production in plants or isolated plant cells.
• the vector is used to transiently express collagen in a plant host and is typically provided as a plant virus vector.
• the expression vectors of the present disclosure can be provided in the form of a "recombinant virus.” If the virus is an RNA virus, the nucleic acid construct of the present disclosure is RNA; if the virus is a DNA virus, the nucleic acid construct is DNA.
• the expression vector provided as the recombinant virus of the present disclosure may be any plant virus vector known to a person skilled in the art to which the present disclosure pertains (for example, "Protein, Nucleic Acid, Enzyme", vol. 45, p. 607- 613 etc.) by a conventional method.
• the tomato bushy stunt virus is modified to be a recombinant virus.
• the present disclosure provides a plant or isolated plant cell containing a nucleic acid construct or expression vector.
• the plant or isolated plant cell may be one that has been subjected to a treatment for introducing a nucleic acid construct or an expression vector, or may be one that has been obtained by growing or multiplying the treated plant or plant cell. .
• the present disclosure includes procollagen or collagen encoded by the nucleic acid construct of the present disclosure.
• the procollagen or collagen is not limited to those produced from plants or isolated plant cells.
• the procollagen or collagen typically has a non-natural amino acid sequence.
• the procollagen or collagen of the present disclosure has 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, or 95% or more of amino acids with respect to natural procollagen or collagen. have sequence identity.
• the procollagen or collagen of the present disclosure may include one or more amino acid substitutions, insertions, or deletions relative to the native procollagen or collagen.
• the procollagen or collagen of the present disclosure can be fused with a heterologous protein in place of the N-terminal pro region, thereby adding various functions.
• fluorescent collagen can be produced by replacing and fusing GFP with the N-terminal pro region.
• the procollagen or collagen can be expressed and purified by any method known to those skilled in the art in the technical field to which this disclosure pertains, and can be used for purposes such as analyzing chemical properties and physiological activities. can.
• the present disclosure provides a composition comprising a procollagen or collagen produced from a plant or an isolated plant cell, or a procollagen or collagen having a non-natural amino acid sequence produced by other methods. provide.
• the aspect of the composition of the present disclosure is not limited, and is provided, for example, in the form of a pharmaceutical composition, a cosmetic composition, or a food composition, and in addition to procollagen or collagen, the composition of each of these fields. It can contain carriers, excipients, etc. that are acceptable in the industry.
• the procollagen or collagen may be in a multimeric state having a fibrous or network-like structure containing a plurality of procollagen or collagen molecules by further intermolecular crosslinking treatment.
• the amount of collagen contained in the composition of the present disclosure is not particularly limited, and is appropriately adjusted depending on the dosage form, purpose, etc.
• the procollagen or collagen-containing pharmaceutical composition of the present disclosure includes cases in which the composition is a drug itself, and compositions that are raw materials or intermediate products for manufacturing a drug.
• the form of the pharmaceutical composition of the present disclosure is not particularly limited, and may be solid, powder, granule, or liquid.
• its dosage form is not particularly limited; for example, it may be a tablet, fine granule, pill, troche, capsule, or a raw material or intermediate product thereof. may be provided.
• the pharmaceutical composition of the present disclosure includes a composition that is a medicine for regenerative medicine or a raw material or intermediate product for manufacturing the same.
• the pharmaceutical composition of the present disclosure is provided as a sheet-like composition, and is provided as a composition for promoting tissue regeneration in or on the body surface of a subject, or as a scaffolding material for culturing sheet-like tissue. can be done.
• the pharmaceutical composition of the present disclosure can be provided as a raw material for a material composition, such as a bioink, for constructing a regenerative medical product having a three-dimensional structure using 3D printing technology or the like.
• the pharmaceutical composition of the present disclosure includes a composition that is an implantable medical device or a raw material or intermediate product for manufacturing the same. These compositions can be used for prevention or treatment of diseases or disorders, cosmetic purposes, and the like. Non-limiting examples of such compositions include wound dressings, artificial skin, artificial blood vessels, catheters and other devices for fluid removal or delivery to patients, artificial hearts, artificial kidneys, orthopedic Including pins, plates and implants.
• the pharmaceutical compositions of the present disclosure can be used as 3D bioprinted post-mastectomy implants, cosmetic surgery fillers.
• Cosmetic compositions containing procollagen or collagen of the present disclosure include cases in which the composition is a cosmetic itself, and compositions that are raw materials or intermediate products for producing cosmetics.
• the form of the cosmetic composition of the present disclosure is not particularly limited, and may be solid, powder, granule, or liquid.
• the cosmetics of the present disclosure may be applied topically or orally, such as topical preparations such as ointments, lotions, creams, microemulsions, gels, oils, solutions, tablets, granules, pills, etc. It can be provided as oral preparations such as troches and capsules, or raw materials or intermediate products thereof.
• the procollagen or collagen-containing food composition of the present disclosure includes cases where the composition is a food itself, and compositions where the composition is a raw material or intermediate product for manufacturing a food.
• Such foods include health foods, functional foods, foods for specified health uses, and foods for the sick, and include feed when used for animals other than humans.
• the form of the food is not particularly limited and may be solid or liquid. Animals other than humans are not particularly limited, and various animals such as mammals, birds, reptiles, amphibians, fish, and insects can be used.
• Specific types of food include, for example, beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and milk drinks; concentrated stock solutions and powders for preparation of these beverages; frozen desserts such as ice cream, ice sherbet, and shaved ice; Noodles such as soba, udon, Harusame, gyoza skin, shumai skin, Chinese noodles, instant noodles; candy, chewing gum, candies, gummies, chewing gum, caramel, chocolate, baked goods such as tablets, snacks, biscuits, jelly, Confectionery such as jam and cream; Fishery and livestock processed foods such as kamaboko, hamburgers, hams, and sausages; Dairy products such as processed milk, fermented milk, yogurt, butter, and cheese; Salad oil, tempura oil, margarine, mayonnaise, shortening, These include, but are not limited to, fats and oil-processed foods such as whipped cream and dressings; seasonings such as sauces and sauces; soups, stews, curries
• Collagen Gene Expression Cassette A synthetic gene encoding Collagen alpha-1 (I) chain (Col1, SEQ ID NO: 8) fused to barley amylase signal peptide (Barley AMY 1.2 Signal Peptide, SEQ ID NO: 5) was generated in CaMV. It was cloned into an expression cassette consisting of the 35S promoter (SEQ ID NO: 1) and the 5'-UTR from Arabidopsis ADH (SEQ ID NO: 3) and the HSP terminator (SEQ ID NO: 4) (FIG. 1a).
• the procollagen after cleavage becomes collagen having a natural N-terminal telopeptide sequence.
• HRV3C cleaves the inside of the recognition sequence, the procollagen after cleavage becomes collagen having an N-terminal telopeptide sequence to which the C-terminal sequence GlyPro of the recognition sequence of HRV3C is added. In plant cells, it is cleaved at a position two amino acid residues (GlnLeu) C-terminal from the natural N-terminal cleavage site.
• a synthetic gene encoding Collagen alpha-2 (I) chain (Col2, SEQ ID NO: 11) fused to barley amylase signal peptide (SEQ ID NO: 5) was transferred to the CaMV 35S promoter (SEQ ID NO: 1) and the Arabidopsis ADH-derived 5'- It was cloned into an expression cassette consisting of the UTR (SEQ ID NO: 3) as well as the HSP terminator (SEQ ID NO: 4) (Fig. 1b).
• Agrobacterium strain GV3101 was transformed by the freeze-thaw method. Agrobacterium transformed with each plasmid was used for infiltration either alone or in a mixture of two strains.
• the plant Nicotiana benthamiana was grown from seed in plug trays filled with commercially available coconut shell substrate. The plants were grown in a greenhouse under a photoperiod of 16 hours light/8 hours dark and a temperature schedule of 25° C. all day. Agroinfiltration was performed on the planted plants 4 weeks after sowing. Immediately prior to implementation, the terminal buds were removed by picking the buds from the plants.
• a synthetic gene encoding BMP1 (SEQ ID NO: 22) fused to a vacuolar signal (SEQ ID NO: 6) or a HN tag (SEQ ID NO: 16) fused to a barley amylase signal peptide (SEQ ID NO: 5) was inserted into the CaMV 35S promoter (SEQ ID NO: 5).
• No. 1 an Arabidopsis ADH-derived 5'-UTR (SEQ ID NO: 3), and an HSP-derived terminator (SEQ ID NO: 4) (Fig. 1f).
• a KDEL sequence was added to the 3' end of the BMP1 gene only when it accumulates in the endoplasmic reticulum.
• a synthetic gene (SEQ ID NO: 23) encoding RNA silencing suppressor p19 (UniProtKB - P50628,) derived from Tomato bushy stunt virus was added to the CaMV 35S promoter (SEQ ID NO: 1) and thaliana ADH-derived 5'-UTR (SEQ ID NO: 3), HSP was cloned into an expression cassette consisting of the derived terminator (SEQ ID NO: 4) (Fig. 1d).
• Total soluble protein was obtained by adding 3 volumes of 50 mM Tris (pH 7.4), 0.15 M NaCl to approximately 0.1 g of frozen and crushed leaves, and grinding at 4°C for 5 minutes for 20,000 g. It was extracted by centrifugation at g. In addition, as another extraction condition, extraction was performed using 3 volumes of 0.5 M acetic acid and 0.2 M NaCl.
• Mass spectrometry samples were separated by reducing all soluble proteins with DTT followed by SDS-PAGE electrophoresis using MOPS buffer. After electrophoresis, the separated proteins were detected by CBB staining, and a band expected to be collagen was observed around 130 kDa in the total soluble protein in which collagen was expressed.
• Mass spectrometry analysis was requested to Nippon Proteomics Co., Ltd. After decolorizing the gel fragment, it was digested with trypsin, and its mass was measured using nanoLC-MS/MS. The data was then subjected to MascotSearch for protein identification (https://www.jproteomics.com/).
• Example 1 Transient expression of secreted type I collagen ⁇ 1 in a plant expression system
• the Col1 expression cassette was transiently expressed in a Nicotiana benthamiana plant expression system using the method described above, and cleaved by SDS-PAGE. The presence or absence of was confirmed ( Figure 2). Samples for each lane are shown below. As a result, it was confirmed that full-length collagen protein having an N-terminal pro-region and a C-terminal pro-region was accumulated in the plant (Fig. 2, lane 3).
• Example 2 Obtaining GFP-fused collagen ⁇ 1 Fluorescence was confirmed by irradiating the extract of GFP-fused collagen ⁇ 1 with excitation light.
• the C-terminal pro-region is said to be necessary for collagen to form triplex chains, but the N-terminal pro-region is not essential and is actually removed. Expression has also been confirmed in the same sequence. This experiment showed that it is possible to produce collagen with new functions by fusing a heterologous peptide sequence such as GFP in place of the N-terminal pro region ( Figure 3).
• Example 3 Confirmation of simultaneous expression of collagen ⁇ 1 and collagen ⁇ 2
• ⁇ 1 and ⁇ 2 collagen proteins were At the same time, it was confirmed by Western blotting that it accumulated within the cell body (Fig. 4). Samples for each lane are shown below. It was also confirmed by mass spectrometry that ⁇ 1 and ⁇ 2 collagen proteins were expressed (Fig. 5). Samples in each lane are the same as in Figure 4.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Zoology (AREA)
• General Health & Medical Sciences (AREA)
• Biophysics (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Physics & Mathematics (AREA)
• Cell Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Plant Pathology (AREA)
• Gastroenterology & Hepatology (AREA)
• Microbiology (AREA)
• Toxicology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Peptides Or Proteins (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=89849383

Family Applications (1)

Country Status (5)

Families Citing this family (1)

Citations (3)

Family Cites Families (1)

• 2023
  • 2023-08-01 EP EP23850083.9A patent/EP4567113A1/en active Pending
  • 2023-08-01 WO PCT/JP2023/028120 patent/WO2024029529A1/ja not_active Ceased
  • 2023-08-01 CN CN202380056688.2A patent/CN119604615A/zh active Pending
  • 2023-08-01 JP JP2024539172A patent/JPWO2024029529A1/ja active Pending
  • 2023-08-01 KR KR1020257001578A patent/KR20250046260A/ko active Pending

Patent Citations (4)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events